Pharmacokinetics of Lopinavir/Ritonavir at Three Different Doses. (ENCORE3)

This study has been completed.
Sponsor:
Information provided by:
Kirby Institute
ClinicalTrials.gov Identifier:
NCT00985543
First received: September 25, 2009
Last updated: March 2, 2011
Last verified: March 2011

September 25, 2009
March 2, 2011
October 2009
January 2010   (final data collection date for primary outcome measure)
Plasma Lopinavir/Ritonavir Concentrations as Measured by the Area Under the Curve (AUC 0-12h). [ Time Frame: at the end of each 7-day dosing phase ] [ Designated as safety issue: No ]
Pharmacokinetics of plasma lopinavir/ritonavir over a 12-hour dosing interval following administration of lopinavir/ritonavir 400/100mg, 200/150mg and 200/50mg twice daily.
Pharmacokinetics of plasma lopinavir/ritonavir over the 12 hours dosing interval following administration to male and female HIV-negative healthy volunteers [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]
Complete list of historical versions of study NCT00985543 on ClinicalTrials.gov Archive Site
Adverse Events [ Time Frame: Up to 11 weeks from screening to final study visit ] [ Designated as safety issue: Yes ]
Number of reported adverse events, severity of adverse events and relationship to study drug was assessed by questions, physical examination and laboratory parameters. Adverse event data was used to assess the safety and tolerability of low lopinavir/ritonavir doses.
Not Provided
Not Provided
Not Provided
 
Pharmacokinetics of Lopinavir/Ritonavir at Three Different Doses.
Pharmacokinetics of Plasma Lopinavir/Ritonavir Over a 12 Hour Dosing Interval Following Administration of 400/100, 200/150, and 200/50 mg Twice Daily to HIV-negative Healthy Volunteers

The purpose of this study is to assess the pharmacokinetics of plasma lopinavir/ritonavir over a 12-hour dosing interval, following administration to male and female HIV−negative healthy volunteers of:

  1. Lopinavir/ritonavir 400/100 mg twice daily
  2. Lopinavir/ritonavir 200/150 mg twice daily
  3. Lopinavir/ritonavir 200/50 mg twice daily

Data during the development of lopinavir/ritonavir showed that lower drug doses had similar efficacy to the standard dose of 400/100mg twice daily. Lower drug doses are also associated with limited toxicity and cost.

The purpose of this study is to assess the pharmacokinetics of plasma lopinavir/ritonavir following administration to male and female HIV−negative volunteers of 400/100mg, 200/150mg and 200/50mg lopinavir/ritonavir twice daily. Each dosing phase will last for 7 days and each phase will be separated by a 7-day wash-out period. Pharmacokinetic evaluations will be made over a 12-hour interval at the end of each dosing phase.

Healthy subjects as determined by their medical history and physical examinations will be eligible to participate in the study. HIV−positive subjects will not be recruited as there is a risk that HIV−resistant mutations will be selected by an experimentally reduced dose of lopinavir/ritonavir. There is no reason to presume that there is any meaningful difference in the metabolic processing of lopinavir/ritonavir between HIV−infected and HIV−uninfected people.

Interventional
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Acquired Immunodeficiency Syndrome
Drug: lopinavir/ritonavir
Each participant received three sequential doses of lopinavir/ritonavir: 400/100 mg twice daily (2 heat-stable 200/50 mg tablets BID), 200/150 mg twice daily (1 heat-stable 200/50 mg tablet BID plus 1 ritonavir 100 mg capsule BID), and 200/50 mg twice daily (1 heat-stable 200/50 mg tablet BID). Each dosing phase lasted for 7 days and each phase was separated by a 7-day wash-out period.
Other Names:
  • Meltrex
  • Ritonavir
  • Active Comparator: LPV/r 400/100 mg
    Lopinavir/ritonavir 400/100 mg twice daily (2 heat-stable 200/50 mg tablets twice daily (BID))
    Intervention: Drug: lopinavir/ritonavir
  • Experimental: LPV/r 200/150 mg
    Lopinavir/ritonavir 200/150 mg twice daily (1 heat-stable 200/50 mg tablet BID plus 1 ritonavir 100 mg capsule BID)
    Intervention: Drug: lopinavir/ritonavir
  • Experimental: LPV/r 200/50 mg
    Lopinavir/ritonavir 200/50 mg twice daily (1 heat-stable 200/50 mg tablet BID)
    Intervention: Drug: lopinavir/ritonavir
Jackson A, Hill A, Puls R, Else L, Amin J, Back D, Lin E, Khoo S, Emery S, Morley R, Gazzard B, Boffito M. Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers. J Antimicrob Chemother. 2011 Mar;66(3):635-40. doi: 10.1093/jac/dkq468. Epub 2010 Dec 17.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
22
January 2010
January 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subjects must meet all of the following inclusion criteria within 28 days prior to the baseline visit:

    1. The ability to understand and sign a written informed consent form, prior to participation in any screening procedures and must be willing to comply with all study requirements
    2. Male or non-pregnant, non-lactating females
    3. Between 18 to 65 years, inclusive
    4. Body Mass Index (BMI) of 18 to 35 kg/m2, inclusive.
    5. Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for a period of at least 1 month after the study

Exclusion Criteria:

  1. Any significant acute or chronic medical illness
  2. Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG or clinical laboratory determinations
  3. Positive blood screen for hepatitis B core and/or C antibodies and/or hepatitis B surface antigen
  4. Positive blood screen for HIV-1 and/or 2 antibodies
  5. Current or recent (within 3 months) gastrointestinal disease
  6. Clinically relevant alcohol or drug use (positive urine drug screen) or history of alcohol or drug use considered by the Investigator to be sufficient to hinder compliance with treatment, follow-up procedures or evaluation of adverse events. Smoking is permitted, but tobacco intake should remain consistent throughout the study
  7. Exposure to any investigational drug or placebo within 3 months of first dose of study drug
  8. Consumption of grapefruit, or Seville oranges or any grapefruit or Seville orange containing product within one week of first dose of study drug and for the duration of the study
  9. Use of any other drugs, including over-the-counter medications and herbal preparations, within two weeks prior to first dose of study drug, unless approved/prescribed by the Principal Investigator as known not to interact with study drugs.
  10. Females of childbearing potential without the use of effective non-hormonal birth control methods, or not willing to continue practising these birth control methods for at least 30 days after the end of the treatment period
  11. Previous allergy to any of the constituents of the pharmaceuticals administered in this trial
Both
18 Years to 65 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United Kingdom
 
NCT00985543
NCHECR-ENCORE3
No
Marta Boffito, Chelsea and Westminster Hospital
Kirby Institute
Not Provided
Principal Investigator: Marta Boffito, MD PhD Chelsea and Westminster Hospital
Kirby Institute
March 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP